Preeclampsia (PE) is an acute hypertensive condition with unknown pathogenesis. It is characterized by hypertension and proteinuria, affects 5–8% of all pregnancies, and is a leading cause of premature iatrogenic deliveries, morbidity, and mortality. PE can lead to potentially life threatening disorders in several organs and in the clotting and the cardiovascular system of the mother, triggering growth restriction and prematurity of the baby. Even in later life, this pathology, PE, can predispose, either the mother or the children, to an increased risk of cardiovascular disease and renal dysfunction.

Effective early prediction and/or intervention of PE are not yet available. On the other hand, as women with history of preeclampsia present an increased risk of future hypertension and cardiovascular diseases, PE management should not be exclusively restricted to the pregnancy period but also extended to the future maternal wellbeing and also to the baby progression throughout adult life, even when this last topic is under intensive research today. Potential topics include, but are not limited to:

• Early preeclampsia prediction and recent biomarkers
• PE treatments and clinical care during pregnancy
• Future risks in children and women with previous history of PE and/or pregnancy hypertension
• Recent advances in preeclampsia pathogenesis

Before submission authors should carefully read over the journal’s Author Guidelines, which are located at http://www.hindawi.com/journals/ogi/guidelines/. Prospective authors should submit an electronic copy of their complete manuscript through the journal Manuscript Tracking System at http://mts.hindawi.com/submit/journals/ogi/ppma/ according to the following timetable: